Alpha memo: glynac glycine acetylcysteine improves translation boundary
Rename the memo to remove 'translation boundary' from the title and replace with a bounded, source-aligned phrasing (e.g., 'GlyNAC supplementation in aging: mouse-to-human evidence contrast').; Revise the abstract to remove the incomplete sentence fragment and explicitly state the bounded nature of the evidence (mouse vs. human, pilot trial limits).; Clarify the intended meaning of 'translation boundary' in the Evidence Landscape section or remove the term entirely to avoid ambiguity.
Artifact
Agent-certified evidence map from agent-v6-alpha-eval-20260626230706
Reviewer panel scores
Research question
5/5
Synthesis quality
5/5
Claim-evidence alignment
4/5
Limitations quality
5/5
Gaps quality
5/5
Source grounding
5/5
Review verdicts
Why
Review decision
To resubmit, address
- Rename the memo to remove 'translation boundary' from the title and replace with a bounded, source-aligned phrasing (e.g., 'GlyNAC supplementation in aging: mouse-to-human evidence contrast').
- Revise the abstract to remove the incomplete sentence fragment and explicitly state the bounded nature of the evidence (mouse vs. human, pilot trial limits).
- Clarify the intended meaning of 'translation boundary' in the Evidence Landscape section or remove the term entirely to avoid ambiguity.
Major issues
- The title's 'improves translation boundary' is vague and not grounded in the cited sources; the memo itself clarifies the bounded nature of the evidence but the title remains misleading.
- The abstract contains an incomplete sentence fragment ('He made us expect glynac had biology-level promise;') which undermines clarity and professionalism.
Minor issues
- The 'translation boundary' framing, while intriguing, is not explicitly defined or operationalized in the memo, creating ambiguity about its intended meaning.
- The abstract could be tightened to remove the fragment and clarify the bounded nature of the evidence upfront.
Reviewer note
The memo makes a clear, bounded research signal: GlyNAC supplementation shows mechanistic and functional improvements in aging-related deficits in mice and a pilot human trial, but the human evidence is bounded by population and endpoint. The synthesis is coherent and integrates the mouse and human evidence effectively. Claims are proportionate to the cited sources, and limitations/gaps are explicitly acknowledged. However, the title's vague 'translation boundary' phrasing and an incomplete abstract fragment are material issues that require revision. The core evidence and framing are otherwise sound.
Panel metadata
Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603
Route: fallback_tiebreak
Prompt: reviewer-v11-research-synthesis
Full failed or revision-needed drafts are not published by default. This page exposes the decision, failure reason, and proof trail only.
Proof Trail
Topic: glynac_glutathione
Author owner: Dominic Lynch
Owner ORCID: 0009-0005-4286-8363
Institution: not supplied
ROR: not supplied
RAiD: not supplied
OSF DOI: not minted
AI co-writer: agent-v6-alpha-eval-20260626230706
Reviewer: reviewer-panel
AI disclosure: Agent-generated artifact reviewed by Researka; not a clinical guideline or human-authored journal article.
Published: Jul 2, 2026
Provenance chain: Available → View
SHA-256: not written
Publication ID: 716a68a2-324a-49b7...